Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nths for those who received modified FOLFOX-6, containing oxaliplatin.
  • Of the 51 patients in the FOLPI treatment arm, 75 percent achieved disease control (defined as complete response, partial response or stable disease); two patients with a complete response, nine patients with a partial response and 27 patients with stable disease. In the FOLFOX treatment arm of 50 patients, 76 percent achieved disease control; three patients with a complete response, 11 patients with a partial response and 24 patients with stable disease.
  • Only 29 percent of the patients who received FOLPI showed evidence of neurotoxicity compared with 60 percent of patients treated with FOLFOX. In addition, 16 percent of FOLFOX-treated patients exhibited severe (Grade 3/4) neurotoxicity, whereas no FOLPI-treated patients showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing alternative to FOLFOX (p<0.0019).
  • With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 percent of the planned picoplatin dose of 150 mg/meter squared was able to be delivered monthly in the 51 patients treated in the FOLPI treatment arm of the trial.
  • Nonhematologic adverse events, including gastrointestinal toxicity, were similar between the treatment groups, with the exception of alopecia, which occurred more frequently with FOLPI.

  • "We continue to be encouraged by these interim, proof-of-concept Phase 2 safety and efficacy results, which suggest the potential of picoplatin in FOLPI as a neuropathy-sparing therapeutic alternative to the use of FOLFOX for the first-line treatment of metast
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
    2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
    3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
    5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
    6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
    7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
    8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
    9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
    10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
    11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... , May 21, 2015 ... the addition of the "North American Active ... by Application (Surgical Wound, & Ulcer), by End-User ... 2019" report to their offering. ,     (Logo: ... market is estimated to grow at a CAGR ...
    (Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
    (Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
    Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
    ... The U.S. Food and Drug Administration today issued new ... needle-free clinical devices to administer influenza vaccinations. Based on ... ) immediately discontinued use of such clinical devices at ... The Kroger family of pharmacies and The Little ...
    ... HAYWARD, Calif., Oct. 21, 2011 Intarcia ... a letter of intent with Quintiles , the world,s ... 3 program for Intarcia,s ITCA 650 (DUROS® subcutaneous continuous delivery ... GLP-1 therapy to better address the unmet needs of the ...
    Cached Medicine Technology:Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes 2Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes 3Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes 4
    (Date:5/22/2015)... 22, 2015 Combination therapy, or ... for chronic obstructive pulmonary disorder (COPD) as the ... AstraZeneca plc as well as Germany’s Boehringer Ingelheim ... position. But will market payers, clinicians and patients ... products to completely new ones? , In spite ...
    (Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
    (Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
    (Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... 16th sweetFrog store located in the Lone Star State. The ... Inc. 500 list of fastest growing companies in 2014. ... for 20 years and love the natural beauty and friendly ... Palestine, sweetFrog locations. “We are really excited about giving back ...
    (Date:5/22/2015)... May 22, 2015 In an effort ... and Sons is offering to donate $5 dollars for ... AC unit or water softening system. Customers have their ... and Sons gets business; and the Special Olympics receives ... Special Olympics helps over 4.4 million athletes, and boasts ...
    Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
    ... 2010) -- Nine-year-old Morgan LaRue is the first cancer patient ... magnetically lengthen her leg, sparing her the possibility of up ... and extension took place at Texas Children,s Cancer Center in ... Center or the device, please see http://bit.ly/MorganLaRue ., On ...
    ... a year in U.S., Canada, study says , FRIDAY, ... in public places across the United States and Canada ... otherwise would die of cardiac arrest each year, researchers ... for defibrillators in more limited setting, such as casinos ...
    ... movement, quality of life, researchers say , FRIDAY, April 16 ... small but significant improvements in their ability to move their ... finds. , The study, by the U.S. Department of ... New England Journal of Medicine , offers the strongest evidence ...
    ... ... in the body. , ... PA (Vocus) April 16, 2010 -- Researchers at Drexel University College of Medicine ... in breast cancer cells and is critical for cancer growth and movement. When researchers reduced ...
    ... ... 2010 targets in the fight against the disease, World Vision’s End Malaria campaign is leading ... to press American congressional leaders to keep investing in programs that are saving the lives ... ...
    ... ... Onyx M.D., announces that they now help physicians find government physician jobs as they ... agencies which provides a new source of locum tenens or temporary physician job opportunities ... ...
    Cached Medicine News:Health News:Texas Children's Cancer Center first in Texas to magnetically lengthen 9-year-old's leg as she grows 2Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Robot-Aided Therapy Can Help Patients Years After Stroke 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 2Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 3Health News:Onyx M.D. Awarded GSA Schedule Contract Creating Increases Access to Government Physician Jobs 2Health News:Onyx M.D. Awarded GSA Schedule Contract Creating Increases Access to Government Physician Jobs 3
    Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
    ... Helmer presents the i.Series ... innovative solutions for the ... sophisticated features than ever ... Refrigerators are at the ...
    ... Designed for the precise requirements of ... Forma Blood Bank Equipment meets American ... National Red Cross (ANRC) and U.S. ... Refrigerators, storage freezers, and platelet incubators ...
    ... Designed for the precise requirements of ... Forma Blood Bank Equipment meets American ... National Red Cross (ANRC) and U.S. ... Refrigerators, storage freezers, and platelet incubators ...
    Medicine Products: